Page 4 - Glenmark Pharmaceuticals

Glenmark gets FDA approval for nasal spray for seasonal allergic rhinitis

Glenmark Pharmaceuticals Limited said its subsidiary Glenmark Specialty S.A. has received US FDA approval for nasal spray fixed dose prescription drug for seasonal allergic rhinitis Ryaltris.

Glenmark gets USFDA nod for nasal spray to treat seasonal allergic rhinitis

Glenmark Pharma on Friday said its subsidiary has received approval from the US health regulator to market Ryaltris, a nasal spray for the treatment of seasonal allergic rhinitis.

Nandish Shah recommends a Bull spread on Glenmark Pharma for January series

Pharma as a sector looking good on the short term chart, according to Nandish Shah of HDFC Securities.

Stocks to Watch: ITC, Lupin, ABFRL, Glenmark, NBFCs, Tata group stocks

The RBI on Tuesday introduced a prompt corrective action (PCA) framework for large non-banking financial companies (NBFCs)

Glenmark arm nets Rs 180 cr in licensing deal for autoimmune antibody

ISB 880 has the potential to treat underserved patients across a range of autoimmune dermatological diseases

Glenmark, Alembic, Cipla: Pharma stocks on a booster dose this December

Select pharma stocks look good on the technical charts and may jump up to 15 per cent in December. On the fundamental side, fears of Omicron variant spreading may also keep them in news and buzzing

S&P upgrades Glenmark to 'BB' on expectation of conservative debt levels

The outlook is stable reflecting the view that Glenmark will maintain its financial policy such that its FFO-to-debt ratio will remain comfortably above 30%, S&P said

Glenmark Pharma PAT grows 10.1%, revenue grows 6.6% in Sept quarter

Glenmark Pharmaceuticals Limited, a research-led global integrated pharmaceutical company, today announced its financial results for the second quarter ended Sept 30, 2021.For the second quarter of FY 2021-22, Glenmark's consolidated revenue was at Rs 31,474 Mn as against Rs 29,525 Mn recording an increase of 6.6%.Consolidated EBITDA was at Rs 5,902 Mn in the quarter ended Sept 30, 2021 as against Rs 5,699 Mn in the previous corresponding quarter, registering an increase of 6.8%.Profit after Tax (PAT) was at Rs 2,577 Mn for the quarter ended Sept 30, 2021 as compared to Rs 2,340 Mn in the previous corresponding quarter, recording a growth of 10.1%."We delivered yet another quarter of consistent performance, both in revenue growth and profitability. We have continued to perform well in our core therapy areas and launched differentiated products." said Glenn Saldanha, Chairman & Managing Director, Glenmark Pharmaceuticals Ltd.He further added, "We have substantially reduced our ...

Glenmark launches unique fixed dose combination drug for diabetes

Glenmark said it has become the first company in the world to launch the fixed dose combination drug in India

Stocks to Watch: Zee, HFCL, Tata Motors, Glenmark, JSW Steel, Vakrangee

Six companies are slated to announce earnings today including BEPL, DRC Systems India, JTL Infra, and Ind Bank Housing

Drug makers Glenmark, Aurobindo Pharma recall products in US market

Glenmark and Aurobindo Pharma are recalling multiple products in the US market due to various reasons like deviation from standard manufacturing protocols and presence of foreign substance

Glenmark Pharmaceuticals sees potential of NONS to prevent Covid-19

The firm, which has tasted success with its oral antiviral drug favipiravir, is now betting on the NONS to drive revenues from its Covid-19 portfolio

Glenmark Pharma gets USFDA nod for generic antibiotic cream

Glenmark Pharma said it has received approval from the US health regulator to market Clindamycin Phosphate Foam, an antibiotic used for treating bacterial infections, in the American market

Glenmark Pharma concludes study on Covid drug Favipiravir in India

Drug firm Glenmark Pharmaceuticals on Wednesday said it has successfully completed its post-marketing surveillance study on Favipiravir in India.

Glenmark Pharma reports revenue growth of 26% and PAT growth of 21% YoY

Glenmark Pharmaceuticals Limited today announced its financial results for the first quarter ended June 30, 2021

Glenmark Pharma Q1 consolidated net profit up 21% at Rs 306 crore

Glenmark Pharmaceuticals on Friday said its consolidated profit after tax (PAT) increased by 21 per cent to Rs 306 crore for the first quarter ended June 30. The Mumbai-based drug major had reported a PAT of Rs 254 crore in the April-June quarter of the 2020-21 fiscal. The company's consolidated revenue rose to Rs 2,965 crore from Rs 2,345 crore in the Q1 of last fiscal. "It was a landmark quarter for the company with positive momentum in all our key markets. Our commitment towards the fight against COVID-19 was reflected in FabiFlu becoming the number one brand in the India pharma market in April. "We launched our first nebuliser, Arformoterol Inhalation solution from Monroe, US," Glenmark Pharmaceuticals Chairman and Managing Director Glenn Saldanha said in a statement. The company has a strategic roadmap to grow consistently and profitably over the year, he added. "We have a clear plan in place to reduce debt by enhancing free cash, prioritising over R&D investments and capita

HNIs incur losses as Glenmark Life Sciences ends flat on listing day

Market observers said HNIs had placed leveraged bets, and lost big as their break even cost was more than Rs 850 per share

Glenmark Life's Rs 1,500 cr IPO subscribed 45x on strong HNI interest

Rolex Rings subscribed 9.3 times a day before close

Back to old normal: Pharma industry returns to pre-pandemic growth level

In this first instalment of a four-part series on how some of the defining numbers in key sectors are springing back to the pre-pandemic level, Sohini Das looks at India's pharmaceutical sector

Centre divests 8% in Hudco, Glenmark Life subscribed 4x on penultimate day

Rolex Rings subscribed 3.5 times on Day-1, Tatva Chintan to list on Thursday